Bristol Myers Squibb Company (NYSE:BMY) Stock Holdings Increased by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. increased its stake in Bristol Myers Squibb by 0.8%, owning approximately 9.41% of the company, valued at around $11.67 billion after acquiring nearly 1.46 million shares in the first quarter.
• In its latest earnings report, Bristol Myers Squibb posted an EPS of $1.46, significantly beating estimates, with revenues reaching $12.27 billion, reflecting a 0.6% year-over-year growth.
• The company declared a quarterly dividend of $0.62, which resulted in a yield of 5.4%, with a current dividend payout ratio of 100%.

Vanguard Group Inc. raised its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 0.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 191,403,004 shares of the biopharmaceutical company's stock after purchasing an additional 1,458,488 shares during the quarter. Vanguard Group Inc. owned 9.41% of Bristol Myers Squibb worth $11,673,669,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Goldman Sachs Group Inc. raised its holdings in shares of Bristol Myers Squibb by 17.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,051,319 shares of the biopharmaceutical company's stock valued at $856,990,000 after buying an additional 2,117,249 shares during the period. Legacy Capital Group California Inc. raised its stake in shares of Bristol Myers Squibb by 114.6% during the first quarter. Legacy Capital Group California Inc. now owns 14,096 shares of the biopharmaceutical company's stock valued at $860,000 after purchasing an additional 7,528 shares during the period. Intrust Bank NA lifted its position in shares of Bristol Myers Squibb by 8.5% during the first quarter. Intrust Bank NA now owns 34,482 shares of the biopharmaceutical company's stock worth $2,103,000 after purchasing an additional 2,691 shares in the last quarter. Westwood Holdings Group Inc. boosted its stake in shares of Bristol Myers Squibb by 67.6% in the first quarter. Westwood Holdings Group Inc. now owns 42,211 shares of the biopharmaceutical company's stock valued at $2,574,000 after purchasing an additional 17,020 shares during the period. Finally, Wealthspire Advisors LLC grew its holdings in Bristol Myers Squibb by 106.2% during the 1st quarter. Wealthspire Advisors LLC now owns 59,144 shares of the biopharmaceutical company's stock valued at $3,607,000 after purchasing an additional 30,465 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock traded up $0.50 during trading hours on Thursday, reaching $45.32. The company's stock had a trading volume of 11,839,864 shares, compared to its average volume of 13,897,906. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33. The company's 50 day simple moving average is $47.36 and its 200 day simple moving average is $51.98. The stock has a market cap of $92.24 billion, a P/E ratio of 18.27, a price-to-earnings-growth ratio of 2.29 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. The company had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. Bristol Myers Squibb's quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.07 earnings per share. As a group, analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.5%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is 100.00%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Wall Street Zen lowered Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Citigroup reduced their target price on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a research note on Friday, August 1st. Finally, Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $56.38.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.